Wellington Management Group
KYMR icon

Wellington Management Group’s Kymera Therapeutics KYMR Stock Holding History

Wellington Management Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421M Sell
3,675,028
-214,659
-6% -$18.4M 0.07% 246
2026
Q1 		$324M Sell
3,889,687
-523,246
-12% -$41.4M 0.06% 273
2025
Q4 		$343M Sell
4,412,933
-782,758
-15% -$52.9M 0.06% 272
2025
Q3 		$294M Sell
5,195,691
-176,370
-3% -$7.95M 0.05% 303
2025
Q2 		$234M Sell
5,372,061
-624,812
-10% -$21.5M 0.04% 323
2025
Q1 		$164M Buy
5,996,873
+689,547
+13% +$25.1M 0.03% 398
2024
Q4 		$214M Buy
5,307,326
+688,967
+15% +$31.1M 0.04% 354
2024
Q3 		$219M Buy
4,618,359
+308,954
+7% +$13.6M 0.04% 372
2024
Q2 		$129M Buy
4,309,405
+15,708
+0.4% +$544K 0.02% 480
2024
Q1 		$173M Sell
4,293,697
-521,861
-11% -$18.7M 0.03% 417
2023
Q4 		$123M Sell
4,815,558
-7,771
-0.2% -$139K 0.02% 519
2023
Q3 		$67M Buy
4,823,329
+646
+0% +$13K 0.01% 628
2023
Q2 		$111M Buy
4,822,683
+531,665
+12% +$15.2M 0.02% 524
2023
Q1 		$127M Sell
4,291,018
-300,071
-7% -$9.68M 0.03% 487
2022
Q4 		$115M Buy
4,591,089
+1,180,703
+35% +$31.5M 0.02% 497
2022
Q3 		$74.2M Sell
3,410,386
-1,624,554
-32% -$42.8M 0.02% 584
2022
Q2 		$99.1M Buy
5,034,940
+1,809,191
+56% +$42.3M 0.02% 540
2022
Q1 		$137M Buy
3,225,749
+530,935
+20% +$22.4M 0.02% 518
2021
Q4 		$171M Buy
2,694,814
+226,879
+9% +$13.2M 0.03% 487
2021
Q3 		$145M Buy
2,467,935
+1,639,994
+198% +$95.1M 0.02% 518
2021
Q2 		$40.2M Buy
827,941
+158,648
+24% +$6.89M 0.01% 895
2021
Q1 		$26M Sell
669,293
-1,021,286
-60% -$61.5M ﹤0.01% 1004
2020
Q4 		$104M Sell
1,690,579
-73,605
-4% -$3.59M 0.02% 580
2020
Q3 		$55.8M Buy
+1,764,184
New +$53.9M 0.01% 669

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group's KYMR Position: Q2 2026 in Review

Wellington Management Group reduced its Kymera Therapeutics (KYMR) stake by 5.5% in Q2 2026, selling an estimated $18.4M and leaving 3,675,028 shares worth $421M. The position accounts for 0.07% of the portfolio, ranked #246.

Wellington Management Group first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Wellington Management Group held 3,675,028 shares of Kymera Therapeutics worth $421M as of Q2 2026.
  • Wellington Management Group sold 214,659 Kymera Therapeutics shares in Q2 2026, an estimated $18.4M.
  • Kymera Therapeutics made up 0.07% of Wellington Management Group's portfolio in Q2 2026, its #246 holding.
  • Wellington Management Group first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.